Malta, 9 April 2008

Circular No. P06/2008

Dear Healthcare Professional,

Re: EMEA concludes new advice to doctors and patients for Tysabri (natalizumab) needed

The European Medicines Agency (EMEA) has concluded that warnings about liver injury should be added to the product information for Tysabri (natalizumab). Following a review of reports of liver injury in patients treated with Tysabri, the EMEA's Committee for Medicinal Products for Human Use (CHMP) has concluded that there is a need to update the product information for Tysabri to warn patients and prescribers that liver injury may occur. The Medicines Authority has participated in these discussions held at the European Medicines Agency (EMEA) and is in agreement with the full **press release** and **Q&A document** issued by the EMEA, attached here for your perusal.

Medicines Authority
198, Rue D'Argens, Gzira, GZR 1368 – Malta.
Tel. (+356) 23439000 Fax. (+356) 23439161 email: info.mru@gov.mt